Patents by Inventor Chris Moyes

Chris Moyes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugate based systems for controlled insulin delivery
    Patent number: 11820805
    Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: November 21, 2023
    Assignee: MERCK SHARP & DOHME LLC
    Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
  • Conjugate based systems for controlled insulin delivery
    Patent number: 11413352
    Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 16, 2022
    Assignee: Merck, Sharp & Dohme LLC
    Inventors: Chris Moyes, Songnian Lin
  • CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
    Publication number: 20210198339
    Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.
    Type: Application
    Filed: December 13, 2018
    Publication date: July 1, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
  • CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
    Publication number: 20210177981
    Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 17, 2021
    Applicants: Merck Sharp & Dohme Corp., SmartCells, Inc.
    Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Yuping Zhu, Dmitri Pissarnitski, Danqing D. Feng, Chris Moyes, Zhiqiang Zhao, David N. Hunter, Songnian Lin, Thomas M. Lancaster, Benjamin Chen